NCT05554341 2026-03-18
Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
49 trialsNCT05564377 2026-03-18
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT04449549 2026-03-09
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT03516279 2026-03-02
Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT01207492 2026-02-20
Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03874858 2026-01-06
DANTE
Novartis
Phase 2 Completed
NCT04626024 2025-12-19
TOKIN
Baylor College of Medicine
Phase 2 Recruiting
NCT03654768 2025-12-18
Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia
SWOG Cancer Research Network
Phase 2 Active not recruiting
NCT03578367 2025-11-10
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Novartis
Phase 2 Completed
NCT02917720 2025-09-22
NAUT
European LeukemiaNet
Phase 2 Active not recruiting
NCT01784068 2025-09-10
ENESTfreedom
Novartis
Phase 2 Completed
NCT01698905 2025-09-02
ENESTop
Novartis
Phase 2 Completed
NCT02029001 2025-08-07
MOST plus
Centre Leon Berard
Phase 2 Recruiting
NCT04838041 2025-07-30
Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
Medical College of Wisconsin
Phase 2 Recruiting
NCT06409936 2025-07-08
PEARL
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Recruiting
NCT01804985 2025-03-14
DESTINY
University of Liverpool
Phase 2 Completed
NCT03906292 2025-03-10
CMLXI
University of Jena
Phase 2 Active not recruiting
NCT05185947 2025-03-07
Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT04126681 2025-03-03
A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase
Ascentage Pharma Group Inc.
Phase 2 Completed
NCT04147533 2024-11-26
HALF
Masaryk University
Phase 2 Active not recruiting
NCT01863745 2024-08-19
Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment
Novartis
Phase 2 Completed
NCT02001818 2024-08-06
PInNACLe
Australasian Leukaemia and Lymphoma Group
Phase 2 Completed
NCT00481052 2022-01-18
CML0307
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Completed
NCT00769327 2022-01-04
CML0408
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Completed
NCT00644878 2021-08-18
MACS0254
Novartis
Phase 2 Terminated
NCT01844765 2021-04-22
DIALOG
Novartis
Phase 2 Completed
NCT01856283 2021-01-13
Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells
Niguarda Hospital
Phase 2 Completed
NCT04578847 2020-10-08
READIT
National Research Center for Hematology, Russia
Phase 2 Unknown
NCT01274351 2020-09-01
Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Novartis
Phase 2 Completed
NCT01528085 2020-07-30
Evaluation of Efficacy and Safety of Nilotinib in Combination With Chemotherapy in Elderly Patients With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Goethe University
Phase 2 Completed
NCT01140568 2020-05-05
Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas
University of California, San Diego
Phase 2 Completed
NCT00036738 2020-01-29
Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT01294618 2019-05-28
NILOPEG
Hospices Civils de Lyon
Phase 2 Completed
NCT02142036 2019-03-13
MetAction
Oslo University Hospital
Phase 2 Completed
NCT00788775 2018-11-15
Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02709083 2018-11-02
Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia
Emory University
Phase 2 Terminated
NCT00809211 2018-07-24
Nilotinib in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Cancer Trials Ireland
Phase 2 Completed
NCT00633295 2017-06-22
Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor
Novartis
Phase 2 Completed
NCT01395121 2017-06-08
NICAM
Institute of Cancer Research, United Kingdom
Phase 2 Completed
NCT01089595 2017-03-15
Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
Fox Chase Cancer Center
Phase 2 Terminated
NCT01110668 2017-02-28
Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
Novartis
Phase 2 Completed
NCT00718562 2017-02-23
Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib
Novartis
Phase 2 Completed
NCT01690065 2016-05-11
NICE-BORA
Ulsan University Hospital
Phase 2 Unknown
NCT00750659 2016-04-20
Nilotinib Pre and Post Allogeneic Stem Cell Transplantation
Sheba Medical Center
Phase 2 Completed
NCT01028222 2015-12-30
TEAM
Novartis
Phase 2 Completed
NCT00782834 2013-04-22
07060
Fox Chase Cancer Center
Phase 2 Terminated
NCT01261429 2013-04-16
Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT)
Centre Leon Berard
Phase 2 Completed
NCT01270893 2012-08-02
Tasigna Neoadjuvant Gastrointestinal Stromal Tumor (GIST)
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT01168050 2011-02-08
NILOMEL
Assistance Publique - Hôpitaux de Paris
Phase 2 Unknown